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Abstract
Aim Despite the widespread assumption that adherence drives glycaemic control, there is little published support for
this in Type 2 diabetes. The study objective was to determine whether self-reported medication adherence predicts future
glycaemic control in Type 2 diabetes, after accounting for baseline control.
Methods Medication adherence (4-item Morisky scale), glycaemic control (HbA1c%), and other variables were
assessed in 287 adult primary care patients prescribed oral medication (40% also on insulin) for Type 2 diabetes.
Glycaemic control was reassessed 6 months later. Regression analyses examined concurrent and future glycaemic
control as a function of baseline medication adherence after adjustment for baseline glycaemia and other potential
confounders.
Results Only half of patients reported high adherence. Cross-sectional adjusted analysis replicated prior reports of an
adherence-HbA1c association (P = 0.011). Even after adjusting for baseline HbA1c, each one-point increase in baseline
Morisky total score was associated with a 1.8 mmol/mol (or 0.16%) increase in HbA1c measured 6 months later.
Additionally, baseline endorsement of forgetting to take medication was associated with a 4.7 mmol/mol (or 0.43%)
increase in 6-month HbA1c (P = 0.005). This effect persisted after adjusting for psychological distress and did not vary
by key demographic and medical features.
Conclusions Even after stringent adjustment for baseline glycaemic control, self-reported adherence to diabetes
medication predicts long-term glycaemic control. The Morisky scale is an easy-to-use clinical tool to identify patients
whose glycaemic control will subsequently worsen, regardless of age, gender and psychological distress.
Diabet. Med. 30, 338–344 (2013)
Introduction
Although a variety of medications improve glycaemic control
in patients with Type 2 diabetes, adherence to insulin and
oral hypoglycaemic agents is often suboptimal [1]. Further-
more, it remains somewhat unclear whether medication
adherence reliably predicts glycaemic control in Type 2
diabetes [2].
Of eight studies that measured adherence by calculating
medication possession ratio from pharmacy refill databases,
seven supported an association with subsequent glycosylated
haemoglobin (HbA1c) [3–9] and one did not [10]. However,
while pharmacy-based measures are sensitive and specific for
the detection of gross non-adherence, they merely indicate
the ceiling of adherence rather than true adherence itself.
Therefore, they overestimate adherence among patients who
take some but not all of their medication, and among those
who do not take their medication on time. Some patients
‘stockpile’ medications by filling their prescriptions on time
without actually using all of their medication. This measure-
ment problem is compounded by the now widespread
availability (in the USA) of automated refills delivered by
mail, through which medication possession is driven by the
passage of time rather than by actual medication consump-
tion. Further bias may be introduced because refill intervals
can vary several months between different pharmacies and
third-party payers. This variation, as well as low-cost
medication purchases from some national chain stores, is
not captured in most databases. Inaccuracies also arise
because of prescribers’ ongoing regimen adjustments and the
obvious mismatch with sliding scale regimens.
Almost all other adherence-HbA1c studies relied upon self-
reported adherence. While their results generally indicate an
association between adherence and HbA1c [11–15], theseCorrespondence to: James E. Aikens. E-mail: aikensj@umich.edu
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studies are virtually all cross-sectional. Because self-reported
adherence could be biased by patients’ foreknowledge of
their laboratory results, these studies may overestimate the
association. Additionally, if cross-sectional associations do
not endure over time, then they are probably clinically
unimportant. In the single existing longitudinal study [16],
clinical records at a specialty diabetes centre were reviewed
over 1 year to assess adherence. Clinician-estimated adher-
ence averaged 80–82% and predicted HbA1c at the end of the
year. However, clinician estimates have a poor correlation
with adherence data collected from other sources [17] and
the non-standardized adherence measure was likely biased by
clinicians’ awareness of patients’ HbA1c.
The goal of this study was to clarify the association
between self-reported medication adherence and glycaemic
control in Type 2 diabetes, using a standardized behavioural
assessment applied to a sample of primary care patients.
Because the preponderance of cross-sectional data support
this association, we hypothesized that adherence predicts
glycaemic control 6 months later, even after stringently
adjusting for baseline HbA1c level.
Subjects and methods
Participants
Potential participants were identified from the administrative
and clinical databases of a large Midwestern urban health-
care system. Eligible patients had Type 2 diabetes as
indicated by either: (1) at least one hospitalization with a
diabetes–related International Classification of Diseases
(ICD)-9 code (250.x, 357.2, 362.0 or 366.41) or (2) at least
two outpatient visits with a diabetes–related ICD–9 code, or
at least one prescription for an oral glucose control medica-
tion, insulin or monitoring supplies. Type 1 diabetes was
further ruled out by telephone screening. Participants also
were required to be between 18 and 80 years of age and able
to complete self-report instruments.
Procedures
The research procedure was pre-approved by our Institu-
tional Review Board (research ethics committee). Eligible
patients were mailed a study invitation, which was followed
by a telephone call for screening and enrolment. After
informed consent, participants attended research appoint-
ments at baseline and 6 months later for assessment of
adherence, glycaemic control and other variables.
Measures
Medication adherence was assessed using theMorisky scale, a
well-validated instrument that elicits information about non-
adherence attributable to forgetting, carelessness, feeling
better and feeling worse [18]. Each item in the scale has a
no/yes format, with a maximum possible score of 4 reflecting
worst possible adherence. Across numerous chronic diseases,
the scale has shown concurrent and predictive validity, as well
as internal consistency [18]. In Type 2 diabetes, it has
demonstrated good reliability and predictive validity, and its
scores are associated with increased HbA1c.[11]. Glycaemic
control (HbA1c) wasmeasuredwith the DCA 2000 [GMI Inc.,
Ramsey, MN, USA; normal range 20–42 mmol/mol (4.0–
6.0%)], which analyses capillary blood samples through a
monoclonal antibody method. Co-morbid medical illnesses
were assessed by abstracting electronic medical records using
a checklist of common medical illnesses used in prior primary
care research (asthma, chronic obstructive lung disease,
congestive heart failure, osteoarthritis, rheumatoid arthritis,
arthritis associated with lupus or scleroderma, peripheral
vascular disease, cirrhosis, chronic hepatitis, coronary artery
disease, thyroid disease, Addison’s disease and Cushing’s
syndrome) [19,20]. Presence of diabetes complications was
measured using a standard self-report checklist of visual,
cardiovascular, kidney, genitourinary and other common
diabetes complications taken from the Diabetes Care Profile
[21]. Diabetes-related distress was measured using the Prob-
lem Areas in Diabetes (PAID) scale [22] and depressive
symptoms were assessed with the Patient Health Question-
naire-9, (PHQ-9) [23]. Participants classified themselves using
US census racial/ethnic categories. Socio-economic status was
assessed using the US Census Bureau Index of Socioeconomic
Status adjusted for the regional Consumer Price Index [24].
Data analysis
Data were analysed using Stata 11.2 software (StataCorp,
College Station, TX, USA). Descriptive analyses were con-
ducted to characterize the sample and distributions were
visually and quantitatively examined for violations of statis-
tical assumptions. A matrix of zero-order Pearson correla-
tions was examined to identify bivariate relationships
between glycaemic control and its potential demographic
and medical confounders, using the criterion of two-tailed
P < 0.05. The relationship between adherence and glycaemic
control was analysed using ordinary least-squares regression
for the prediction of 6-month glycaemic control before and
after adjusting models for baseline HbA1c values and other
covariates. Standardized beta coefficients (b) were estimated




Of 420 patients screened by telephone, 332 met entry
criteria, 287 (86%) of whom consented and provided
baseline data. Consent was unrelated to age and gender,
although African-Americans were more likely to consent
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than Caucasians (62 vs. 52%, P = 0.025). Thirty-four
participants (12%) dropped out after baseline, leaving 253
study completers. Attrition was significantly associated with
being under 60 years of age (85% of dropouts vs. 74% of
non-dropouts, P < 0.014) and being African-American (74
vs. 55%, P = 0.036), but was not significantly related to
gender, socio-economic status, medication adherence or poor
glycaemic control.
Sample characteristics
The sample was demographically and medically diverse
(Table 1). Almost half of participants were women and 57%
were African-American. Age range was from 27 to 88 years
(mean 56.4 ± 8.7) and, as previously reported, was positively
correlated with adherence (r = 0.15, P = 0.012) [25]. Socio-
economic status was distributed across its entire range and in
approximate agreement with expected levels, except for a
possible shift from the ‘upper–middle’ into the ‘middle’
strata. Baseline HbA1c was generally elevated [mean
60 ± 19 mmol/mol (7.7 ± 1.7% units); 59% with HbA1c
 53 mmol/mol (or above 7.0%)], 40% were prescribed
insulin in addition to an oral hypoglycaemic agent, diabetes
duration ranged from 1 to 60 years, complications were
common and 20% had at least two significant co-morbid
medical conditions. Based upon Morisky scores, 51% of
patients could be classified with high adherence (score of 0),
42% with medium adherence (score of 1–2) and 7% with
low adherence (score of 3–4). Item-level responses indicated
that the most frequently endorsed reasons for non-adherence
were forgetting (39%) and carelessness (25%).
Bivariate associations
Preliminary bivariate analysis indicated that poor baseline
glycaemic control was associated with being younger
(r = 0.30, P < 0.001), male (r = 0.16, P = 0.006), African-
American (r = 0.16, P = 0.006) and on insulin (r = 0.16,
P = 0.006), as well as having fewer co-morbid medical
conditions (r = 0.17, P = 0.005). These variables were
therefore selected as control covariates for subsequent
analyses. Because socio-economic status was not significantly
related to either adherence or glycaemic control (P = 0.468
and 0.606, respectively), it was not selected as a covariate.
Concurrent analyses of baseline glycaemic control
We used multiple regression analyses to evaluate the
association between medication adherence and concurrent
glycaemic control. Medication adherence had a significant
zero-order (unadjusted) association with baseline glycaemic
control (b = 0.21, P = 0.001). This effect remained statisti-
cally significant after adjusting for the demographic and
medical confounders that were identified above (see Table 2,
upper panel; b = 0.14, P = 0.011). In order to identify
specific adherence item(s) to analyse, glycaemic control was
simultaneously regressed on all four Morisky scale items and
the above covariates. Only item 1 was a significant predictor
(P = 0.023). When substituted for the Morisky total in the
above model, item 1 likewise predicted concurrent glycaemic
control (b = 0.13, P = 0.018).
Longitudinal analyses predicting glycaemic control
Parallel linear regression models were developed to evaluate
the association between medication adherence at baseline
and glycaemic control 6 months later, before and after
adjusting for confounders and baseline glycaemic control (see
Table 2, lower panel). Medication adherence had a zero-
order association with future glycaemic control (b = 0.25,
P < 0.001), which persisted when the model included
Table 1 Characteristics of baseline sample (n = 287)
Variable Mean ± SD or %
Age 56.4 ± 8.7
Female gender 48
African-American ethnicity 57








60 ± 19 (7.7 ± 1.7)
HbA1c  53 mmol/mol (7.0%) 59
Diabetes duration (years) 10.8 ± 8.0
Number of diabetes complications 4.3 ± 1.1
Prescribed insulin in addition to
oral hypoglycaemic agents
40









1. Forget to take 39
2. Careless at times 25
3. Sometimes stop taking when
feel better
7
4. Sometimes stop taking if you
feel worse
8
*US Census Bureau Index of Socioeconomic Status, adjusted for
current inflation and regional Consumer Price Index.
†Scoring instructions do not distinguish between lower–middle
and lower strata.
‡IFCC mmol/mol (DCCT%); normal range: 20–42 mmol/mol
(4.0–6.0%).
§Morisky medication adherence scale; higher scores reflect
worse adherence.
¶Percentages are given for the response of ‘yes’, which reflects
worse adherence.
DCCT, Diabetes Control and Complications Trial; IFCC,
International Federation of Clinical Chemistry and Laboratory
Medicine.
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potential confounders (b = 0.19, P = 0.003), as well as
baseline glycaemic control (b = 0.09, P = 0.025). The
unstandardized beta coefficient for adherence indicated that
each unit increase in Morisky score (range 0–4) was
associated with a 1.8 mmol/mol (or 0.16% unit) increase
in HbA1c. Finally, when Morisky scale item 1 was substi-
tuted for the total score in the fully adjusted model, it
similarly predicted glycaemic control (b = 0.12, P = 0.005).
An affirmative response to item 1 was associated with a
4.7 mmol/mol (or 0.43% unit) increase in HbA1c. Both fully
adjusted models explained 63% of the variance in 6-month
glycaemic control (P < 0.001).
Post hoc analyses
As is often the case, Morisky and HbA1c score distributions
were somewhat skewed in the positive direction. However,
similar findings emerged when adherence and glycaemic
control data were transformed using either log or rank
functions (all P < 0.013). Because the adherence data could
be considered ordinal, analyses were also repeated, with
adherence categorized as high vs. medium or low. Again,
identical results were obtained (P = 0.037). Additional anal-
yses explored whether further adjustment for baseline psy-
chological distress (diabetes-specific distress and depressive
symptoms) reduced the effect of medication adherence.
However, neither distress variable had a significant unique
association with glycaemic control (both P > 0.254), whereas
the effect of medication adherence remained statistically
significant (P = 0.018) after distress measures were included
in the model. Analyses were also conducted to examine
whether medication adherence interacted with any of the
baseline variables, which would indicate whether the effect of
medication adherence on metabolic control was concentrated
within any identifiable subgroup of patients. However,
medication adherence did not significantly interact with age,
gender, ethnicity or co-morbid medical conditions (P > 0.351
for all interaction terms). There was no indication that the
longitudinal association between adherence and 6-month
HbA1c levels differed between patients who did and did not
use insulin (P = 0.308). Adherence similarly did not interact
with having a baseline elevation of either diabetes-related
distress (P = 0.535) or depressive symptoms (P = 0.876).
Discussion
To summarize the results, self-reported medication adher-
ence was suboptimal for 49% of primary care patients with
Type 2 diabetes prescribed either oral medication alone or
with insulin. The most frequently endorsed reasons for non-
adherence were forgetting (39%) and carelessness (25%).
Overall adherence and non-adherence attributable to forget-
ting were each significantly associated with concurrent and
subsequent glycaemic control. These associations, previously
reported only in cross-sectional studies, appear to persist for
at least 6 months. Both the concurrent and longitudinal
Table 2 Results of regression analyses of concurrent and future glycaemic control






b b P b b P
Baseline HbA1c* (n = 287) Age 0.62 0.28 < 0.001 — — —
Female gender 5.24 0.14 0.011 — — —
African-American ethnicity 3.63 0.10 0.090 — — —
Prescribed insulin 4.58 0.12 0.033 — — —
Co-morbid medical conditions† 1.33 0.06 0.383 — — —
Medication adherence total‡§ 2.63 0.14 0.011 — — —
Non-adherence attributable to forgetting§¶ 5.07 0.15 0.015 — — —
Month 6 HbA1c* (n = 253) Age 0.54 0.23 < 0.001 0.18 0.08 0.083
Female gender 0.28 0.01 0.904 2.55 0.07 0.100
African-American ethnicity 4.36 0.11 0.074 1.57 0.04 0.333
Prescribed insulin 3.35 0.09 0.160 0.05 0.00 0.974
Co-morbid medical conditions† 0.83 0.03 0.602 0.05 0.01 0.960
Baseline HbA1c* — — — 0.81 0.74 < 0.001
Medication adherence total‡§ 3.58 0.19 0.003 1.77 0.09 0.025
Non-adherence attributable to forgetting§¶ 9.00 0.23 < 0.001 4.68 0.12 0.005
*In International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) (mmol/mol) units; analysis of HbA1c% would change
unstandardized beta estimates (b), but standardized betas (b) and P levels would not change.
†Coded as 0, 1,  2.
‡Morisky scale continuous total score (higher scores reflect worse adherence).
§Evaluated without the other adherence score in the model. Covariate effects were estimated with only the Morisky total score in the model
and did not change appreciably when item 1 was substituted.
¶Morisky scale item 1: (forget to take; ‘yes’ = 1).
Bold font indicates statistically-significant associations.
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associations are independent of key demographic and med-
ical factors such as age, gender, ethnicity, insulin use, medical
co-morbidity and baseline glycaemic control. Further adjust-
ment for both diabetes-specific distress and depressive
symptoms did not attenuate the effect, and exploratory
interaction analysis suggested that the effect is constant
across major demographic categories, the presence of diabe-
tes complications and the use of insulin. Therefore, a simple-
to-administer self-report measure has considerable practical
prognostic value across a variety of patient characteristics.
We believe that ours is the first longitudinal study of self-
reported adherence and glycaemic control in Type 2 diabe-
tes, although Type 1 diabetes has been more thoroughly
investigated in this regard. As such, this report confirms and
significantly extends existing conclusions drawn from cross-
sectional and refill-based study designs. Because the Morisky
adherence measure does not estimate the percentage of
medication doses taken as directed, the results cannot be
meaningfully compared with refill-based studies. Notwith-
standing, only half of patients reported being highly adher-
ent, with the majority of the remainder emerging as
moderately adherent. Because self-report generally tends to
yield inflated adherence estimates, actual medication adher-
ence was probably somewhat lower than we observed.
The findings also highlight the predictive validity of self-
reported adherence. In psychometric terms, predictive valid-
ity is the extent to which test scores predict performance on a
relevant future criterion and, as such, it is a more stringent
psychometric characteristic than concurrent validity. In this
study, each one unit increase in Morisky score (range 0–4)
was associated with a 1.8 mmol/mol (0.16% unit) increase in
HbA1c, which is approximately twice the effect size reported
in an earlier study of Morisky scores and concurrent HbA1c
(11). Likewise, reported difficulty remembering to take
medication was associated with a 4.7 mmol/mol (or 0.43%
unit) increase in HbA1c. These findings are important
because self-report has been criticized as an excessively
subjective and upwardly-biased approach to estimating
regimen adherence. Because refill-based adherence estimates
can also be problematic because of the increased use of
lengthy refill intervals and difficulty applying to sliding scale
insulin regimens, self-reported diabetes regimen adherence
using a standardized scale represents a valid and practical
method for use in research and clinical settings.
No interactions with medication adherence were detected.
That is, adherence effects are constant across demographic
and medical strata defined by age, gender, ethnicity, insulin
use and medical co-morbidity. Lack of interaction with
distress furthermore suggests that the longitudinal effects of
adherence are not concentrated among patients with either
diabetes-related distress or depressive symptoms, despite
recent findings that depression–glycaemia associations are
concentrated among insulin users [26,27]. In other words,
the clinical usefulness of Morisky scores seems to generalize
across numerous patient characteristics.
Study limitations
While the longitudinal design enabled us to address several
alternative explanations, this study was fundamentally
naturalistic, which led to some multi-collinearity among
the predictors. Although we reported both unadjusted and
adjusted estimates so that readers may compare them,
randomization to standardized conditions would have more
completely controlled this. We considered only medication
adherence, whereas adherence to other aspects of the
diabetes diet, physical activity and blood glucose self-
monitoring are also important and should be assessed in
future studies. Although the Morisky measure covers oral
medications as well as insulin, it is impossible to isolate
adherence to either medication among patients who use
both and it does not measure proportion of medication
taken. As with medication possession indices, self-report
may lead to inflated estimates. However, Morisky scores
were validated against medication refill data [28,29] and
correlate with concurrent metabolic control [11]. Although
attrition was higher among younger and African-American
patients, these groups remained well represented and the
data analyses adjusted for these characteristics. Because we
oversampled African-Americans, the findings may not
generalize to all Caucasian or Latino/Hispanic patients.
Arguing against this possibility, no interactions with
ethnicity or other demographic variables were detected
and demographic variance was accounted for. While the
current study extends the evidence base to include rela-
tionships with glycaemic control over time, future studies
should replicate and extend this inquiry across a longer
period of time. Although little support was found for
potential statistical interactions and other alternative expla-
nations, statistical power to detect these effects may have
been limited by the inclusion of additional main effect and
interaction terms in the model.
Clinical implications
The findings imply that poor adherence is influential
enough to affect future glycaemic control, regardless of
current control. This impact is greater than that of either
diabetes-specific or generalized psychological distress,
implying that adherence is a key issue even among non-
distressed patients. Clinical efforts to improve glycaemic
control thus should emphasize medication-taking regardless
of whether or not there is a need for distress alleviation.
While our item-level results suggest that the most impor-
tant adherence strategies will be those that directly reduce
forgetting, such as automated reminders [31], regimen
simplification [30] and regimen tailoring [32], additional
validated strategies are electronic monitoring [33] and
motivational interviewing [34]. Finally, at a practical level,
between one and four easy-to-administer questions could
be routinely incorporated into clinical diabetes assessments
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when the goal is to achieve or maintain glycaemic control.
Caution is warranted, however, because demand charac-
teristics and social desirability bias may affect how even a
well-validated research tool performs when it is adminis-
tered in clinical practice.
Conclusions
Self-reported adherence to Type 2 diabetes medication is
robustly associated with glycaemic control 6 months later,
even after adjusting for baseline glycaemic control, level of
psychological distress, diabetes characteristics and socio-
demographic features. Clinicians may be able to use brief
self-report measures to efficiently identify those in need of
adherence interventions to prevent poor diabetes outcomes.
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